• Home
  • NEW DAY MEDICINE
  • 8 (82) 2025
  • 65 -8 (82) 2025 - Eldor I.A. - THE RELATIONSHIP BETWEEN IMMUNO-INFLAMMATORY BIOMARKERS AND NEUROPSYCHOLOGICAL CHANGES IN PARKINSON’S DISEASE

65 -8 (82) 2025 - Eldor I.A. - THE RELATIONSHIP BETWEEN IMMUNO-INFLAMMATORY BIOMARKERS AND NEUROPSYCHOLOGICAL CHANGES IN PARKINSON’S DISEASE

THE RELATIONSHIP BETWEEN IMMUNO-INFLAMMATORY BIOMARKERS AND NEUROPSYCHOLOGICAL CHANGES IN PARKINSON’S DISEASE

Eldor I.A. - Tashkent State Medical University

Resume

This article investigates the correlation between immunological biomarkers and neuropsychological impairments in Parkinson’s disease. The study involved 155 PD patients and 20 healthy controls. Serum levels of IL-6, TNF-β, CRP, IgE, and IL-10 were measured using ELISA. Cognitive and affective functions were assessed using the RAVLT, GAD-7, and BDI scales. The findings revealed a significant association between elevated pro-inflammatory cytokines and the severity of cognitive decline and depressive symptoms. These immune markers may serve as prognostic indicators and contribute to personalized diagnostic and therapeutic approaches in PD.

Keywords: Parkinson’s disease, IL-6, TNF-β, immune biomarkers, cognitive impairment, depression, ELISA, neuropsychological assessment.

First page

365

Last page

368

For citation:Eldor I.A. - THE RELATIONSHIP BETWEEN IMMUNO-INFLAMMATORY BIOMARKERS AND NEUROPSYCHOLOGICAL CHANGES IN PARKINSON’S DISEASE//New Day in Medicine 8(82)2025 365-368 https://newdayworldmedicine.com/en/new_day_medicine/8-82-2025

List of References

  1. World Health Organization. Parkinson’s Disease Fact Sheet. Geneva, 2021.
  2. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124(8):901–905.
  3. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382–397.
  4. Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson’s disease. J Parkinsons Dis. 2013;3(4):493–514.
  5. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord. 2004;10(Suppl 1):S3–S7.
  6. Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl. 2000;(58):143–151.
  7. Reale M, Iarlori C, Thomas A, et al. Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun. 2009;23(1):55–63.
  8. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 in CSF of Parkinson’s patients. Neurosci Lett. 1995;202(1–2):17–20.
  9. Rentzos M, Nikolaou C, Anastasopoulos D, et al. Interleukin-10 and interleukin-12 in Parkinson’s disease. Acta Neurol Scand. 2009;119(5):332–337.
  10. Brochard V, Combadière B, Prigent A, et al. CD4+ T cells and neurodegeneration in Parkinson model. J Clin Invest. 2009;119(1):182–192.
  11. Tansey MG, Romero-Ramos M. Immune system responses in Parkinson’s disease. Eur J Neurosci. 2019;49(3):364–383.
  12. Whitton PS. Inflammation as a causative factor in Parkinson's disease. Br J Pharmacol. 2007;150(8):963–976.

    file

    download